



COMPARISON

OF THE

WHO ATC CLASSIFICATION

&

EphMRA/PBIRG ANATOMICAL

CLASSIFICATION

VERSION April 2016

Comparison of the WHO ATC Classification and EphMRA / PBIRG Anatomical Classification

The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence.

In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified.

WHO mainly classifies **substances** according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product).

EphMRA classifies **products**, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only.

The purposes of classification are also different:

The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring.

This classification is recommended by the WHO for use in international drug utilisation research.

The EphMRA/PBIRG classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.

The aim of harmonisation is to reach a “full” agreement of all mono substances in a given class as listed in the WHO ATC Index, mainly at third level: whenever this is not possible, or harmonisation of third level is too difficult or makes no sense (e.g. C2, R3), the second level will be taken as the reference class.

Harmonisation is not a simple adaptation of two systems; harmonisation is clearly an improvement of the existing systems.

In view of the increasing use of the WHO classification by national and international authorities and institutions with different objectives, it is opportune to have a harmonised classification.

The main benefit is that all parties involved in a given topic, use the same definitions, same substances, and therefore the discussions are easier.

In line with the harmonisation procedure of WHO/EphMRA, this booklet has been prepared to facilitate cross-comparison. The comparison has been based on the WHO guidelines. Whenever possible, we have checked all molecules included in the current WHO/ATC Index with the EphMRA coding.

We have tried to simplify the document and for this reason and according to the pre-agreed mandate of harmonisation, only the 3rd level has been used as a point of reference. However, in some cases (e.g. A2B1 antiulcer and group L) we have also mentioned the 4th levels in our comparison. Where the two groups are similar, on the EphMRA side only the code and the title has been added.

Where a difference exists, this has been notified using the following symbols:

- ❖ This class/code does not exist (e.g. A03B)
- ☉ The heading or the content of this class may be different (e.g. N5C).
- These substances are classified in a different class.
- + This class is covered by more than one EphMRA/PBIRG or WHO class

A lot of discrepancies concern rather obsolete products for which there is no need for harmonisation (e.g. products withdrawn from the market, sales of minor importance).

We hope this booklet will improve both the use and understanding of the two systems, in particular for those companies in which the two systems are used by different departments (medical and marketing).

The Committee has tried to make a comprehensive comparison of both systems, but cannot guarantee a 100% level of accuracy.

For complete guidelines on the WHO ATC systems refer to “Guidelines for ATC classification” and for the EphMRA/PBIRG Anatomical classification system refer to “EphMRA / PBIRG classification”.

To obtain the guidelines please contact:

Norwegian Institute of Public Health WHO Collaborating Centre for Drug Statistics Methodology P.O. Box 4404 Nydalen N-0403 OSLO Fax: +47-23408146 email: whocc@fhi.no web: www.whocc.no	Bernadette Rogers EphMRA General Manager Tel: +44 161 304 8262 Email: generalsecretary@ephmra.org	Carol Reilly Executive Director, PBIRG 1758 Allentown Road, Box 209 Lansdale, PA 19446 USA Telephone: [1] 215 855 5255 Fax: [1] 215 855 5622 Email: creilly@pbirg.com
--	--	--

WHO (Substance based)

EphMRA (Product based)

-
- A ALIMENTARY TRACT AND METABOLISM**
- A01 STOMATOLOGICAL PREPARATIONS**
- A01A STOMATOLOGICAL PREPARATIONS
- Preparations for the treatment of **throat** infections (lozenges for common cold conditions) are classified in **R02** - Throat preparations.
 - Cevimeline is classified in N7A.



-
- A02 DRUGS FOR ACID RELATED DISORDERS**
- A02A ANTACIDS
- Plain antitflatulents, see A02BX
-
- A02B DRUGS FOR PEPTIC ULCER and GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
- A02B A H2-receptor antagonists
- A02B B Prostaglandins
- A02B C Proton pump inhibitors
- A02B D Combinations for eradication of Helicobacter pylori
- A02B X Other drugs for peptic ulcer and gastro-oesophageal disease (GORD)
- Chlorbenzoxamine is classified in A03A.

-
- A ALIMENTARY TRACT AND METABOLISM**
- A1 STOMATOLOGICALS, MOUTH PREPARATIONS, MEDICINAL DENTIFRICES ETC.**
- A1A STOMATOLOGICALS
- Products indicated for both the **posterior part of the mouth and throat** infections are classified in **R2A** or **A1A** depending on **their main indication**.
 - +
 - Cevimeline is classified here.
- A1B MOUTH ANTIFUNGALS

-
- A2 ANTACIDS, ANTIFLATULENTS AND ANTI-ULCERANTS**
- A2A ANTACIDS, ANTIFLATULENTS, CARMINATIVES
- Plain antitflatulents are classified in this group.
-
- A2B ANTIULCERANTS
- A2B1 H2 antagonists
- A2B3 Prostaglandin antiulcerants
- A2B2 Proton pump inhibitors
- Combinations for eradication of Helicobacter pylori are classified here.
- A2B4 Bismuth antiulcerants
- +
-

WHO (Substance based)

EphMRA (Product based)

		A2B9	All other anticulcerants ➤ Chlorbenzoxamine is classified here.
A02X	OTHER DRUGS FOR ACID RELATED DISORDERS	A2C	OTHER STOMACH DISORDER PREPARATIONS
A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	A3	FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS
A03A	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ➤ Chlorbenzoxamine is classified here. ➤ Trimebutine is classified here. ➤ Alosetron is classified here (A03A E).	A3A	PLAIN ANTISPASMODICS AND ANTICHOLINERGICS ➤ Chlorbenzoxamine is classified in A2B9. ➤ Trimebutine is classified in A3F. ➤ Alosetron is classified in A3G.
+			
A03B	BELLADONNA AND DERIVATIVES, PLAIN	❖	
A03C	ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS	A3C	ANTISPASMODIC/ATARACTIC COMBINATIONS
A03D	ANTISPASMODICS IN COMBINATION WITH ANALGESICS ➤ Combinations with both psycholeptics and analgesics are classified in A03E A.	A3D	ANTISPASMODIC/ANALGESIC COMBINATIONS ➤ Combination of both ataractic and analgesic are classified here.
A03E	ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS		
A03E A	Antispasmodics, psycholeptics and analgesics in combination ➤ Antispasmodics in combination with psycholeptics, analgesics and other agents are classified in this group.		➤ Combinations of both ataractics and analgesics are classified in A3D.
A03E D	Antispasmodics in combination with other drugs	A3E	ANTISPASMODICS COMBINED WITH OTHER PRODUCTS

WHO (Substance based)

EphMRA (Product based)

A03F PROPULSIVES
➤ Trimebutine is classified in A03A.

A3F GASTROPROKINETICS
➤ Trimebutine is classified here.

❖
➤ Alosetron is classified in A03A E.
➤ Tegaserod is classified in A06A X.
➤ Linaclotide is classified in A06A X.
➤ Lubiprostone is classified in A06A X.

A3G GASTRO-INTESTINAL SENSORIMOTOR MODULATORS
➤ Alosetron is classified here.
➤ Tegaserod is classified here.
➤ Linaclotide is classified here when indicated in IBS-c (290mcg), but in A6A when indicated in chronic constipation (145mcg).
➤ Lubiprostone is classified here when indicated in IBS-c (8mcg), but in A6A when indicated in chronic constipation (24mcg).
➤ Other drugs for constipation, including laxatives, are classified in A6A.

A04 ANTIEMETICS AND ANTINAUSEANTS

A04A ANTIEMETICS AND ANTINAUSEANTS
➤ Antihistamines are classified in R06A.

A4 ANTIEMETICS AND ANTINAUSEANTS

A4A ANTIEMETICS AND ANTINAUSEANTS
➤ Antihistamines used in motion sickness are classified here.

A05 BILE AND LIVER THERAPY

A05A BILE THERAPY

A05B LIVER THERAPY, LIPOTROPICS

A05C DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION

A5 CHOLAGOGUES AND HEPATIC PROTECTORS

A5A BILE THERAPY AND CHOLAGOGUES

A5B HEPATIC PROTECTORS, LIPOTROPICS

A5C CHOLAGOGUE/LIPOTROPIC COMBINATIONS

A06 DRUGS FOR CONSTIPATION

A06A DRUGS FOR CONSTIPATION
➤ Tegaserod is classified here.

A6 DRUGS FOR CONSTIPATION AND BOWEL CLEANSERS

A6A DRUGS FOR CONSTIPATION
➤ Tegaserod is classified in A3G.

WHO (Substance based)

- Linaclotide is classified here.
- Lubiprostone is classified here.

EphMRA (Product based)

+

- Linaclotide is classified here when indicated in chronic constipation (145mcg) but in A3G when indicated in IBS-c (290mcg).
- Lubiprostone is classified here when indicated in chronic constipation (24mcg) but in A3G when indicated in IBS-c (8mcg).

A6B BOWEL CLEANSERS

A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY / ANTIINFECTIVE AGENTS

A07A INTESTINAL ANTIINFECTIVES

A07B INTESTINAL ADSORBENTS

- Ceratonia is classified in A07X.

A07C ELECTROLYTES WITH CARBOHYDRATES

A07D ANTIPROPULSIVES

A07E INTESTINAL ANTIINFLAMMATORY AGENTS

- Vedolizumab is classified in L04A.

A07F ANTIDIARRHEAL MICROORGANISMS

A07X OTHER ANTIDIARRHEALS

- Ceratonia is classified here.

A08 ANTI OBESITY PREPARATIONS, EXCL. DIET PRODUCTS

A08A ANTI OBESITY PREPARATIONS, EXCL. DIET PRODUCTS

A7 ANTIDIARRHOEALS, ORAL ELECTROLYTE REPLACERS AND INTESTINAL ANTIINFLAMMATORIES

A7A INTESTINAL ANTIINFECTIVE ANTIDIARRHOEALS

A7B INTESTINAL ABSORBANT ANTIDIARRHOEALS

- Ceratonia is classified here.

A7G ORAL ELECTROLYTE REPLACERS

A7H MOTILITY INHIBITORS

A7E INTESTINAL ANTIINFLAMMATORY AGENTS

- Vedolizumab is classified here.

A7F ANTIDIARRHOEAL MICRO-ORGANISMS

A7X ALL OTHER ANTIDIARRHOEALS

- Ceratonia is classified in A7B.

A8 ANTI OBESITY PREPARATIONS, EXCL. DIETETICS

A8A ANTI OBESITY PREPARATIONS, EXCL. DIETETICS

WHO (Substance based)

- Amphetamine is classified in N06B.
- Liraglutide is classified in A10B.

EphMRA (Product based)

- Amphetamine, when indicated as antiobesity product, is classified here.
- Liraglutide for weight management only is classified here.

A09 DIGESTIVES, INCL. ENZYMES

A09A DIGESTIVES, INCL. ENZYMES

- Bromelains is classified in B06A A.
- Chymotrypsin and trypsin are classified in B06A A when used as haematological enzymes.

A9 DIGETIVES, INCL. DIGESTIVE ENZYMES

A9A DIGESTIVES, INCL. DIGESTIVE ENZYME

- Bromelains is classified here or, D3 and V3H depending on indications.
- Chymotrypsin is classified here or in C5B, D3A, M2A and V3H depending on indications.
- Trypsin is classified here or in V3H and V3X depending on indications.

A10 DRUGS USED IN DIABETES

A10A INSULINS and ANALOGUES

A10 DRUGS USED IN DIABETES

A10C HUMAN INSULINS and ANALOGUES

+

A10D ANIMAL INSULINS

A10B ORAL BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

- Guar gum is classified here.
- Exenatide is classified here (A10B X).
- Liraglutide is classified here.

A10H SULPHONYLUREA ANTIDIABETICS
A10J BIGUANIDE ANTIDIABETICS
A10J1 BIGUANIDE ANTIDIABETICS, PLAIN
A10J2 BIGUANIDE AND SULPHONYLUREA ANTIDIABETIC COMBINATIONS
A10J9 BIGUANIDE ANTIDIABETIC COMBINATIONS, OTHER
A10K GLITAZONE ANTIDIABETICS
A10K1 GLITAZONE ANTIDIABETICS, PLAIN
A10K2 GLITAZONE AND SULPHONYLUREA ANTIDIABETIC COMBINATIONS
A10K3 GLITAZONE AND BIGUANIDE ANTIDIABETIC COMBINATIONS
A10K9 GLITAZONE ANTIDIABETIC COMBINATIONS, OTHER
A10L ALPHA-GLUCOSIDASE INHIBITOR ANTIDIABETICS
A10M GLINIDE ANTIDIABETICS
A10M1 GLINIDE ANTIDIABETICS, PLAIN
A10M3 GLINIDE AND BIGUANIDE ANTIDIABETIC COMBINATIONS
A10M9 GLINIDE ANTIDIABETIC COMBINATIONS, OTHER
A10N DPP-IV INHIBITOR ANTIDIABETICS
A10N1 DPP-IV INHIBITOR ANTIDIABETICS, PLAIN
A10N3 DPP-IV INHIBITOR AND BIGUANIDE ANTIDIABETIC COMBINATIONS
A10N9 DPP-IV INHIBITOR ANTIDIABETIC COMBINATIONS, OTHER

WHO (Substance based)

EphMRA (Product based)

		A10P A10S	SGLT2 INHIBITORS GLP-1 AGONIST ANTIDIABETICS ➤ Liraglutide for weight management only is classified in A8A.
A10X	OTHER DRUGS USED IN DIABETES Includes aldose reductase inhibitors. ➤ Guar gum is classified in A10B. ➤ Thioctic acid is classified in A16A. ➤ Combinations of DPP-IV inhibitors with statins are classified in A10B H.	A10X A10X1	OTHER DRUGS USED IN DIABETES Antidiabetic multitherapy combination products. Includes combinations of antidiabetics with cardiovascular drugs where the aim is to treat both the diabetes and the cardiovascular condition. Also includes combinations of antidiabetics with anti-obesity drugs where the aim is to treat both the diabetes and the obesity.
		A10X9	Other drugs used in diabetes. ➤ Guar gum is classified here.. ➤ Thioctic acid is classified here or A16A.
A11	VITAMINS Vitamin B ₁₂ is classified in B03.	A11	➤ VITAMINS Vitamin B ₁₂ is classified in A11F, which is a code only used in the EphMRA/PBIRG system.
A12	MINERAL SUPPLEMENTS	A12	MINERAL SUPPLEMENTS
A12A	CALCIUM Products indicated for hyperphosphatemia only are classified in V03AE. Other calcium supplement products are classified here.	A12A	CALCIUM PRODUCTS ➤ Products indicated for hyperphosphatemia and calcium deficiency are classified in V03G2.
A12B	POTASSIUM	A12B	POTASSIUM PRODUCTS
A12C	OTHER MINERAL SUPPLEMENTS	A12C	OTHER MINERAL SUPPLEMENTS
A13	TONICS	A13	TONICS
A13A	TONICS	A13A	TONICS

WHO (Substance based)

EphMRA (Product based)

The large number of products in this class make it impossible to fully state that they are equal.

A14 ANABOLIC AGENTS FOR SYSTEMIC USE**A14A ANABOLIC STEROIDS****A14B OTHER ANABOLIC AGENTS**

A14 ANABOLICS, SYSTEMIC**A14A ANABOLIC HORMONES, SYSTEMIC****A14B OTHER ANABOLIC AGENTS, SYSTEMIC**

A15 APPETITE STIMULANTS

- Cyproheptadine is classified in R06A.
- Pizotifen is classified in N02C.

A15 APPETITE STIMULANTS

- Cyproheptadine when indicated as appetite stimulant, is classified here, otherwise it is classified in R6A.
- Pizotifen is classified here; when indicated for migraine, is classified in N2C.

A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS**A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS**

- Includes levocarnitine, ademetionine, thioctic acid.
- Zinc acetate is classified here.

A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS**A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS**

- Levocarnitine is classified here but when indicated for ischaemic disorders, it is classified in C1X.
 - Ademetionine is classified in N6A.
 - Thioctic acid is classified here or in A10X.
 - Combinations of diabetes and cardiovascular products are classified in A10X1.
 - Zinc acetate is classified in V3E when indicated for Wilson's disease.
-

WHO (Substance based)

B	BLOOD AND BLOOD FORMING ORGANS
B01	ANTITHROMBOTIC AGENTS
B01A	ANTITHROMBOTIC AGENTS
☞	
B01A A	Vitamin K antagonists
B01A B	Heparin group
	➤ Antithrombin III is classified here.
	➤ Danaparoid is classified here.
B01A C	Platelet aggregation inhibitors excl. heparin
	➤ Dipyridole is classified here.
	➤ Defibrotide is classified in B01A X.
	➤
B01A D	Enzymes
☞	➤ Protein C and activated Protein C are classified here.
B01A E	Direct thrombin inhibitors
B01A F	Direct factor Xa inhibitors
B01A X	Other antithrombotic agents
	➤ Defibrotide is classified here.

EphMRA (Product based)

B	BLOOD AND BLOOD FORMING ORGANS
B1	ANTITHROMBOTIC AGENTS
☞	
B1A	VITAMIN K ANTAGONISTS
B1B	HEPARINS
	➤ Antithrombin III is classified in B2C.
	➤ Danaparoid is classified in B1X.
B1C	PLATETLET AGGREGATION INHIBITORS
	➤ Dipyridole is classified here; when indicated for coronary therapy it is classified in C1D.
	➤ Defibrotide is classified here.
	➤
B1D	FIBRINOLYTICS
☞	➤ Protein C and activated Protein C are classified in B1X.
B1E	DIRECT THROMBIN INHIBITORS
B1F	DIRECT FACTOR XA INHIBITORS
B1X	OTHER ANTITHROMBOTIC AGENTS
	➤ Defibrotide is classified in B1C.

WHO (Substance based)

EphMRA (Product based)

B02 ANTIHEMORRHAGICS

B02A ANTIFIBRINOLYTICS

B02A A Amino acids

B02A B Proteinase inhibitors

- Alfa 1 antitrypsin (alpha-1-proteinase inhibitor) is classified here.

B02B VITAMIN K AND OTHER HEMOSTATICS

B02B A Vitamin K

- Protamin is classified in V03A.
- Idarucizumab is classified in V03A

B02B B Fibrinogen

B02B C Local hemostatics

B02B D Blood coagulation factors

❖

- Eltrombopag and romiplostim are classified in B02B X.

B02B X Other systemic hemostatics

- Eltrombopag and romiplostim are classified here.

B03 ANTIANEMIC PREPARATIONS

B03A IRON PREPARATIONS

B2 BLOOD COAGULATION SYSTEM, OTHER PRODUCTS

B2A ANTIFIBRINOLYTICS

B2C PROTEINASE INHIBITORS

- Alpha-1-proteinase inhibitor (alfa 1 antitrypsin) is classified in R3X.

B2B ANTAGONISTS (ANTIDOTES TO ANTICOAGULANTS)

B2B1 Vitamin K

B2B2 Protamin sulphate

B2B9 Antidotes to anticoagulants, other

- Idarucizumab is classified here.
-

B2F TISSUE SEALING PREPARATIONS

- Local hemostatics are classified in D3A

B2D BLOOD COAGULATION

B2E THROMBOPOIETIN AGONISTS

- Eltrombopag and romiplostim are classified here.

B2G SYSTEMIC HAEMOSTATICS

- Eltrombopag and romiplostim are classified in B2E.

B3 ANTI-ANAEMIC PREPARATIONS

B3A HAEMATINICS, IRON & ALL COMBINATIONS

WHO (Substance based)

EphMRA (Product based)

-
- All plain iron preparations and all combination products containing more than 30 mg Fe per defined daily dose (DDD), are classified here, even if they contain multivitamins.

- Combinations of iron with multivitamins are classified in A11A.

B03B VITAMIN B12 AND FOLIC ACID

B3B LIVER EXTRACTS AND COMBINATIONS WITH B12



B03B A Vitamin B12 (cyanocobalamin and analogues)

A11F PLAIN VIT B12

B03B B Folic acid and derivatives

B3X OTHER ANTI-ANAEMIC PRODUCTS, INCLUDING FOLIC ACID, FOLINIC ACID

- Folinic acid is classified in V03A.

- Folinic acid with more than one indication classified in V3D.

B03X OTHER ANTIANEMIC PREPARATIONS

B03X A Other antianemic preparations

B3C ERYTHROPOIETIN PRODUCTS



B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS

K HOSPITAL SOLUTIONS



B05A BLOOD AND RELATED PRODUCTS

K3B PROTEIN SOLUTIONS

+

B05A A Blood substitutes and plasma protein fractions

K2 PLASMA EXPANDERS

B05B I.V. SOLUTIONS

B05B A Solutions for parenteral nutrition

K1 INTRAVENOUS SOLUTIONS

+

B05B B Solutions affecting the electrolyte balance

- Trometamol is classified here.

- Trometamol is classified in K4B.

WHO (Substance based)

EphMRA (Product based)

B05B C	Solutions producing osmotic diuresis	K1F	SOLUTIONS FOR OSMOTIC THERAPY
B05C	IRRIGATING SOLUTIONS	K5	IRRIGATING SOLUTIONS
B05D	PERITONEAL DIALYTICS	K6B	PERITONEAL DIALYSIS SOLUTIONS
B05X	I.V. SOLUTION ADDITIVES	K4	INJECTION SOLUTIONS/INFUSION ADDITIVES
B05Z	HEMODIALYTICS AND HEMOFILTRATES		
B05Z A	Hemodialytics, concentrates	K6A	HAEMODIALYSIS SOLUTIONS
B05Z B	Hemofiltrates	K6C	HAEMOFILTRATION
B06	OTHER HEMATOLOGICAL AGENTS	B6	ALL OTHER HAEMATOLOGICAL AGENTS
B06A	OTHER HEMATOLOGICAL AGENTS	❖	
B06A A	Enzymes	B6B	HYALURONIDASE
	➤ Chymotrypsin and trypsin are classified here when used as haematological enzymes.	+	
		B6C	OTHER HEMATOLOGICAL AGENTS
			➤ Chymotrypsin is classified in A9A, C5B, D3A, M2A or V3H depending on indications.
			➤ Trypsin is classified in A9A, V3H or V3X depending on indications.
B06A B	Other hem products	B6C	OTHER HEMATOLOGICAL AGENTS
	➤ Ruxolitinib is classified in L01XE.		➤ Ruxolitinib is classified in L1H.
B06A C	DRUGS USED IN HEREDITARY ANGIOEDEMA	B6D	HEREDITARY ANGIOEDEMA PRODUCTS

WHO (Substance based)

EphMRA (Product based)

C CARDIOVASCULAR SYSTEM

C01 CARDIAC THERAPY

C01A CARDIAC GLYCOSIDES

C01B ANTIARRHYTHMICS, CLASS I AND III

- Adenosine is classified in C01E
-

C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

C01C A Adrenergic and dopaminergic agents

- Caffeine, plain is classified in N06B.
 - Heptaminol is classified in C01D.
 - Dihydroergotamine is classified in N02C.
-

C01C E Phosphodiesterase Inhibitors



+

C01C X Other cardiac stimulants

C01D VASODILATORS USED IN CARDIAC DISEASES

C01D A Organic nitrates

- Amyl nitrite is classified in V03A.

C01D B Quinolone vasodilators

- Flosequinan is classified here.

C CARDIOVASCULAR SYSTEM

C1 CARDIAC THERAPY

C1A CARDIAC GLYCOSIDES AND COMBINATIONS

C1B ANTI-ARRHYTHMICS

- Adenosine is classified here
-

C1C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

- Caffeine, plain is classified here.
 - +
 - Heptaminol is classified here.
 - Dihydroergotamine is classified here and in N2C.
-

C1F POSITIVE INOTROPIC AGENTS

Includes substances such as amrinone, milrinone, fenoximone, piroximone, xamoterol.

C1E NITRITES AND NITRATES

- Amyl nitrite is classified here and V3A.



- Flosequinan is classified in C1D.

WHO (Substance based)

EphMRA (Product based)

C01D X Other Vasodilators used in cardiac diseases

- Prenylamine is classified here.
- Heptaminol is classified here.
- Serelaxin is classified here.
- Nesiritide is classified here.
- Dipyrnidol is classified in B01A C.
- Trimetazidine is classified in C01E B.
- Ivabradine is classified in C01E B.
- Flosequinan is classified in C01D B.

C1D CORONARY THERAPY EXCL. CALCIUM ANTAGONISTS AND NITRITES

- Prenylamine is classified in C8A.
- Heptaminol is classified in C1C.
- Dipyrnidol is classified here and in B1C.
- Nesiritide is classified in C1X.
- Trimetazidine is classified here.
- Ivabradine is classified here.
- Flosequinan is classified here.

C01E OTHER CARDIAC PREPARATIONS

- Adenosine is classified here.
- Levocarnitine is classified in A016.
- Trimetazidine is classified here.
- Ivabradine is classified here.
- Nesiritide is classified in C01D X

C1X ALL OTHER CARDIAC PREPARATIONS

- Adenosine is classified in C1B.
- Levocarnitine is classified in this group when indicated for ischaemic disorders (in A16 if for nutrition problems).
- Ivabradine is classified in C1D.
- Nesiritide is classified here.

C02 ANTIHYPERTENSIVES

- Mebutamate is classified in N05B.
- Terazosin is classified in G04C.
- Bosentan, ambrisentan, macitentan, riociguat and sitaxentan are classified in C02KX.

C2 ANTIHYPERTENSIVES

- Mebutamate is classified in C2A.
- Terazosin is classified here and in G4C.
- Bosentan, ambrisentan, macitentan, riociguat and sitaxentan are classified in C6A.
- Indoramin for migraine is classified in N2C9.

C03 DIURETICS

- Cicletanine is classified here.

C3 DIURETICS

- Cicletanine is classified in C2A.
-

WHO (Substance based)

EphMRA (Product based)

C04 PERIPHERAL VASODILATORS

C4 CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS

WHO (Substance based)

EphMRA (Product based)

C04A PERIPHERAL VASODILATORS

- Cinnarizine and flunarizine are classified in N07C.
- Nimodipine is classified in C08.
- Citicoline is classified in N06B.
- Visnadine is classified here.

C4A CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS

- Cinnarizine and flunarizine can be classified here and also in N2C and N7C depending on indications.
- Nimodipine is classified here.
- Citicoline is classified here.
- Visnadine is classified in C1D.

C05 VASOPROTECTIVES

C5 ANTIVARICOSIS/ANTIHAEMORRHOIDAL PREPARATIONS

C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE

C5A TOPICAL ANTI-HAEMORRHOIDALS

C05B ANTIVARICOSE THERAPY

- Chymotrypsin is classified in B06A A when used as haematological enzymes.

C5B VARICOSE THERAPY, TOPICAL

- Chymotrypsin is classified here or in A9A, D3A, M2A and V3H depending on indications.

C05C CAPILLARY STABILIZING AGENTS

C5C VARICOSE THERAPY, SYSTEMIC



- Bosentan, ambrisentan, macitentan, riociguat and sitaxentan are classified in C02KX. Iloprost is classified in B01A C.
- Sildenafil is classified in G04B E.

C6 OTHER CARDIOVASCULAR PRODUCTS

- Ambrisentan, bosentan, macitentan, riociguat and sitaxentan are classified here.
- Iloprost is classified here or in B1C depending on indication.
- PDE5 inhibitors indicated only for pulmonary arterial hypertension are classified here.

C07 BETA BLOCKING AGENTS

C7 BETA BLOCKING AGENTS

C07A BETA BLOCKING AGENTS

C7A BETA BLOCKING AGENTS, PLAIN

WHO (Substance based)

EphMRA (Product based)

C07B BETA BLOCKING AGENTS AND THIAZIDES

+

C07C BETA BLOCKING AGENTS AND OTHER DIURETICS

+

C07D BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS

+

C07E BETA BLOCKING AGENTS AND VASODILATORS

C07F BETA BLOCKING AGENTS AND OTHER ANTIHYPERTENSIVES

- Combinations with calcium channel blockers are classified here.

C7B BETA BLOCKING AGENTS, COMBINATIONS



- Combinations with calcium channel blockers are classified in C8B.
- Combinations with angiotensin-II inhibitors are classified in C9D.

C08 CALCIUM CHANNEL BLOCKERS

- Nimodipine is classified here.
- Prenylamine is classified in C01D X.
- Combinations with beta blockers are classified in C07F.

C8 CALCIUM ANTAGONISTS

- Nimodipine is classified in C4A.
- Prenylamine is classified here.
- Combinations with beta blockers are classified in C8B2.

C08C SELECTIVE CCB WITH MAINLY VASCULAR EFFECT

+

C08D SELECTIVE CCB WITH DIRECT CARDIAC EFFECTS

+

C08E NON-SELECTIVE CALCIUM CHANNEL BLOCKERS

C8A CALCIUM ANTAGONISTS, PLAIN

WHO (Substance based)

EphMRA (Product based)

C8G CALCIUM CHANNEL BLOCKERS AND DIURETICS



C8B1 CALCIUM ANTAGONISTS COMBINATIONS WITH ANTIHYPERTENSIVES (C2) AND/OR DIURETICS

C8B2 CCB/BETABLOCKER COMBINATIONS

C8B3 CCB COMB. WITH OTHER DRUGS OF GROUP C, except C7-C10

C8B4 CCB COMBINATIONS WITH ALL OTHER DRUGS

C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C9 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C09A ACE INHIBITORS, PLAIN

C9A ACE INHIBITORS, PLAIN

C09B ACE INHIBITORS, COMBINATIONS

C9B ACE INHIBITORS, COMBINATIONS



C09C ANGIOTENSIN II ANTAGONISTS, PLAIN

C9C ANGIOTENSIN II ANTAGONISTS, PLAIN

C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
➤ Combinations with beta-blockers are classified in C07F.

C9D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
➤ Combinations with beta-blockers are classified here.

C09X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C9X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C10 LIPID MODIFYING AGENTS

C10 LIPID-REGULATING/ANTI-ATHEROMA PREPARATIONS

C10A LIPID MODIFYING AGENTS, PLAIN

C10A CHOLESTEROL AND TRIGLYCERIDE REGULATING PREPARATIONS

C10A A HMG CoA reductase inhibitors

C10A 1 Statins (HMG-CoA reductase inhibitors)

C10A B Fibrates

C10A 2 Fibrates

WHO (Substance based)

EphMRA (Product based)

C10A C Bile acid sequestrants

❖ PCSK9 inhibitors is classified in C10AX

C10A D

+ Nicotinic acid and derivatives

C10A X Other lipid modifying agents

- Colestilan is classified in V03A.
- PCSK9 inhibitors are classified here.

❖

C10B LIPID MODIFYING AGENTS, COMBINATIONS

- Lipid-regulating cardiovascular multitherapy combination products are classified here.

❖

- Lipid-regulating cardiovascular multitherapy combination products are classified in C10B

C10A 3 Ion-exchange resins

- Colestilan is also classified in V3G.

C10A4 PCSK9 inhibitors

C10A 9 All other cholesterol/triglyceride regulators

C10 B ANTI-ATHEROMA PREPARATIONS OF NATURAL ORIGIN

C10C LIPID REGULATORS IN COMBINATION WITH OTHER LIPID REGULATORS

- Lipid-regulating cardiovascular multitherapy combination products are classified in C11A.

C11 CARDIOVASCULAR MULTI-THERAPY COMBINATION PRODUCTS

C11A LIPID-REGULATING CARDIOVASCULAR MULTI-THERAPY COMBINATION PRODUCTS

WHO (Substance based)

EphMRA (Product based)

D DERMATOLOGICALS

D01 ANTIFUNGALS FOR DERMATOLOGICAL USE

D01A ANTIFUNGALS FOR TOPICAL USE

- Topical metronidazole is mainly used for rosacea and is classified in D06B X.
- Combinations with corticosteroids are classified here.

D01B ANTIFUNGALS FOR SYSTEMIC USE

- Terbinafine is classified here.

D02 EMOLLIENTS AND PROTECTIVES

D02A EMOLLIENTS AND PROTECTIVES

- + ➤ Aminobenzoic acid is classified in D02B.

D02B PROTECTIVES AGAINST UV-RADIATION

- Betacarotene is classified here.
- Aminobenzoic acid is classified here.

D DERMATOLOGICALS

D1 ANTIFUNGALS, DERMATOLOGICAL

D1A1 Topical dermatological antifungals

- Products indicated for the treatment of rosacea are classified in D10A.
- Combinations with corticosteroids are in D7B2.

D1A2 Systemic dermatological Antifungals

- Terbinafine is classified in J2A.

D2 EMOLLIENTS, PROTECTIVES

D2A EMOLLIENTS, PROTECTIVES

- Aminobenzoic acid is classified here.

- Betacarotene is classified in D11A.
-
-

WHO (Substance based)

EphMRA (Product based)

D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS

- Local haemostatics are classified in B02B.
- Bromelains is classified in B06A A.
- Chymotrypsin is classified in B06A A when used as haematological enzymes.

D3 WOUND HEALING AGENTS

- Local haemostatics are classified here.
- Bromelains is classified here or in A9A and V3H depending on indications.

D03A CICATRIZANTS



D03B ENZYMES

- D03B A
- Bromelains is classified here.



- Bromelains is classified in A9A, D3A or V3H depending on indications.

D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.

D4 ANTIPRURITICS, INCL. TOPICAL ANTIHISTAMINES, ANAESTHETICS, ETC.

D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC

- Nalfurafine is classified in V03A.

D4A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANAESTHETICS, ETC.

- Nalfurafine is classified here.

D05 ANTIPSORIATICS

D5 NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS

D05A ANTIPSORIATICS FOR TOPICAL USE

D5A TOPICAL ANTIPSORIASIS PRODUCTS

WHO (Substance based)

- D05B ANTIPSORIATICS FOR SYSTEMIC USE
- Alefacept and ustekinumab are classified in L04A.
 - Methotrexate is classified in L01B and L04A.

- ❖
- Topical tacrolimus is classified in D11A.
 - Alitretinoin is classified in D11A.
 - Aminolevulinic acid is classified in L01X.

EphMRA (Product based)

- D5B SYSTEMIC ANTIPSORIASIS PRODUCTS
- Alefacept and ustekinumab when indicated for psoriasis are classified here.
 - Ustekinumab when indicated for psoriasis and also for other conditions is classified in L4C.
 - Methotrexate is classified in D5B, M1C and L1B.
 - Ustekinumab is classified here.

- D5X OTHER NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS
- Topical tacrolimus is classified here.
 - Alitretinoin is classified in here when indicated for the treatment of eczema, and in L1X1 when indicated to treat cutaneous lesions in Kaposi's sarcoma.
 - Aminolevulinic acid is classified here and in L1X.
 - Products containing ingenol mebutate or diclofenac gel that are indicated for actinic keratosis are classified here

WHO (Substance based)

EphMRA (Product based)

D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE

- Metronidazole for the treatment of rosacea is classified here.
- Dressings with anti-infectives are classified in D09A A.

D06A ANTIBIOTICS FOR TOPICAL USE

D06B CHEMOTHERAPEUTICS FOR TOPICAL USE
(- D6B B)

D06B B Antivirals

D6C ANTIBIOTICS AND CHEMOTHERAPEUTICS,
COMBINATIONS

D6 TOPICAL ANTIBACTERIALS AND ANTIVIRALS

- Metronidazole for treatment of rosacea is classified in D10A.
- Dressings with anti-infectives are classified here.

D6A TOPICAL ANTIBACTERIALS

D6A TOPICAL ANTIBACTERIALS

D6D TOPICAL ANTIVIRALS INFECTION PRODUCTS

❖ Included in D6A

WHO (Substance based)

EphMRA (Product based)

D07 **CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS**

D7 **TOPICAL CORTICOSTEROIDS**

D07A CORTICOSTEROIDS, PLAIN

D7A PLAIN TOPICAL CORTICOSTEROIDS

D07B CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS

D7B TOPICAL CORTICOSTEROID COMBINATIONS

+

D07C CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS

❖

+

D07X CORTICOSTEROIDS, OTHER COMBINATIONS

❖

D08 **ANTISEPTICS AND DISINFECTANTS**

D8 **ANTISEPTICS AND DISINFECTANTS**

D08A ANTISEPTICS AND DISINFECTANTS

D8A ANTISEPTICS AND DISINFECTANTS

D09 **MEDICATED DRESSINGS**



❖

THE PRODUCTS OF THIS CLASS HAVE BEEN ALLOCATED TO THE DIFFERENT GROUPS

D09A MEDICATED DRESSINGS

This group comprises medicated dressings, ointment dressings etc. Liquid wound protectives are classified in D02A D – Liquid plasters. Local hemostatics, eg. Gauze, tampons etc. are classified in B02B C – Local hemostatics.

D09A A Ointment dressings with antiinfectives

Included
in
D6A

TOPICAL ANTIBIOTICS AND/OR SULPHONAMIDES

WHO (Substance based)

EphMRA (Product based)

D09A B Zinc bandages

Included
in
D5A

TOPICAL ANTIPSORIASIS AND SIMILAR PRODUCTS

D09A X Soft paraffin dressings

Included
in
D2A

EMOLLIENTS, PROTECTIVES

D10 ANTI-ACNE PREPARATIONS

D10 ANTI-ACNE PREPARATIONS

D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE

D10A TOPICAL ANTI-ACNE PREPARATIONS

- Metronidazole for the treatment of rosacea is classified in D06B.
- Brimonidine is classified in D11A and in S1E for ocular indications.
- Nadifloxacin is classified here.
- Non-ophthalmic sulfacetamide is classified here.

- Metronidazole for the treatment of rosacea is classified here.
- Brimonidine is classified here and in S1E for ocular indications.
- Nadifloxacin is classified here and in D6A when indicated for skin bacteriosis.
- Non-ophthalmic sulfacetamide is classified here and in D6A when indicated for skin bacteriosis.

D10B ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE

D10B ORAL ANTI-ACNE PREPARATIONS

- Antibiotics, such as tetracyclines and erythromycin, which are also used for the treatment of acne are classified in group J.
- Combinations of estrogen and antiandrogen, used for the treatment of acne, are classified in group G03H.

- Antibiotic products, specifically indicated for the treatment of acne are classified here.
 - Combinations of estrogen and cyproterone, specifically indicated for the treatment of acne, are classified here.
-

WHO (Substance based)

EphMRA (Product based)

D11 OTHER DERMATOLOGICAL PREPARATIONS**D11A OTHER DERMATOLOGICAL PREPARATIONS**

- Androgens for topical use are classified here.
- Tacrolimus and pimecrolimus are classified here.
- Alitretinoin is classified here.
- Brimonidine is classified here and in S1E for ocular indications.
- Ivermectin is classified here and in P02C.

D11 OTHER DERMATOLOGICAL PREPARATIONS**D11A OTHER DERMATOLOGICAL PREPARATIONS**

- Androgens for topical use are in D3A.
 - Tacrolimus is classified in D5X and L4A; pimecrolimus in D5X.
 - Alitretinoin is classified in D5X when indicated for the treatment of eczema, and in L1X1 when indicated to treat cutaneous lesions in Kaposi's sarcoma.
 - Brimonidine is classified in D10A and in S1E for ocular indications.
 - Ivermectin is classified in P1B and in P3A, depending on indication.
-

WHO (Substance based)

EphMRA (Product based)

G	GENITO URINARY SYSTEM AND SEX HORMONES
G01	GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
G01A	ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
+	➤ All oral and rectal dosage forms of imidazole derivatives are classified in P01A.
G01B	ANTIINFECTIVES AND ANTISEPTICS, IN COMBINATION WITH CORTICOSTEROIDS

G	GENITO-URINARY SYSTEM AND SEX HORMONES
G1	GYNAECOLOGICAL ANTI-INFECTIVES
G1A	TRICHOMONACIDES
+	➤ Dosage forms used for treatment of gynaecological infections are classified here.
	➤ Rectal suppositories for topical trichomonocides are classified in J8B.
G1B	GYNAECOLOGICAL ANTIFUNGALS
+	
G1C	GYNAECOLOGICAL ANTIBACTERIALS
+	
G1D	GYNAECOLOGICAL ANTISEPTICS

G02	OTHER GYNAECOLOGICALS
	➤ Analgesics used in dysmenorrhea are classified in N02B.

G2	OTHER GYNAECOLOGICALS
	➤ Analgesics indicated exclusively for dysmenorrhea are classified in G2X1.

G02A	UTEROTONICS
	➤ Oxytocin and demoxytocin are classified in H01B.

G2A	LABOUR INDUCERS
	➤ Oxytocin and demoxytocin are classified here.

G02B	CONTRACEPTIVES FOR <u>TOPICAL</u> USE
	➤ IUDs containing progestogens are classified here.

G2B	TOPICAL CONTRACEPTIVES
	➤ IUDs with progestogens are classified in G3A.

G02C	OTHER GYNECOLOGICALS
	➤ Vaginal forms of estrogens are classified in G03C.

❖	
	➤ Vaginal forms of estrogens are classified in G2F.

G02C A	Sympathomimetics, labor repressants
--------	-------------------------------------

G2E	LABOUR INHIBITORS
-----	-------------------

❖	
	➤ Vaginal forms of estrogens are classified in G03C.

G2F	TOPICAL SEX HORMONES
	➤ Vaginal forms of estrogens are classified here.

WHO (Substance based)

EphMRA (Product based)

G02C B	Prolactin inhibitors <ul style="list-style-type: none">➤ Lisuride tablets in high strength (0.2mg) are classified in this group, while low dose tablets (25 mcg) are classified in N02C.➤ Bromocriptine low dose is classified here; high strength tablets are classified in N04B.➤ Cabergoline low dose is classified here, high strength tablets are classified in N04B.
G02C C	Antiinflammatory products for vaginal administration
+	
G02C X	Other gynaecologicals

G2D	PROLACTIN INHIBITORS <ul style="list-style-type: none">➤ Lisuride is classified in N4A.➤ Bromocriptine is classified here and N4A.➤ Cabergoline is classified here and N4A.
G2X	OTHER GYNAECOLOGICAL PRODUCTS

G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

G3 SEX HORMONES AND PRODUCTS WITH SIMILAR DESIRED EFFECTS, SYSTEMIC ACTION ONLY

G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE <ul style="list-style-type: none">➤ IUDs with progestogens are classified in G02B.➤ Ulipristal when indicated for emergency contraception is classified here. It is also classified in G03X.➤ Mifepristone is classified in G03XB.
------	---

G3A	HORMONAL CONTRACEPTIVES, SYSTEMIC <ul style="list-style-type: none">➤ IUDs with progestogens are classified here.➤ Ulipristal when indicated for emergency contraception is classified here. It is also classified in G3X.➤ Mifepristone (10-25 mg) when indicated for emergency contraception is classified here. It is also classified in G3X.
-----	--

G03B ANDROGENS

G3B ANDROGENS, EXCLUDING G3E, G3F

G03C	ESTROGENS <ul style="list-style-type: none">➤ Tibolone is classified here.➤ Vaginal forms are classified here.
------	---

G3C	OESTROGENS, EXCLUDING G3A, G3E, G3F <ul style="list-style-type: none">➤ Tibolone is classified G3X.Vaginal forms are classified G2F.
-----	---

G03D	PROGESTOGENS <ul style="list-style-type: none">➤ Flumedroxone is classified in N02C.
------	---

G3D	PROGESTOGENS, EXCLUDING G3A,G3F <ul style="list-style-type: none">➤ Flumedroxone is classified here.
-----	--

WHO (Substance based)

EphMRA (Product based)

G03E	ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION	G3E	ANDROGEN WITH FEMALE HORMONE COMBINATIONS
G03F	PROGESTOGENS AND ESTROGENS IN COMBINATION <ul style="list-style-type: none">➤ Estradiol and cyproterone in combination is classified in G03H B.	G3F	OESTROGEN WITH PROGESTOGEN COMBINATIONS, EXCLUDING G3A <ul style="list-style-type: none">➤ Estradiol and cyproterone in combination is classified here.
G03G	GONADOTROPHINS AND OTHER OVULATION STIMULANTS	G3G	GONADOTROPHINS, INCL.OTHER OVULATION STIMULANTS
G03H	ANTIANDROGENS <ul style="list-style-type: none">➤ All plain cyproterone preparations (and combinations of cyproterone and estrogen) regardless of indication are classified here.	❖	<ul style="list-style-type: none">➤ Plain cyproterone preparations are classified in G3X and L2B depending on indication.
❖	<ul style="list-style-type: none">➤ Bazedoxifene, lasofoxifene, ospemifene and raloxifene are classified in G03X.	G3J	SERMS (SELECTIVE OESTROGEN RECEPTOR MODULATORS) <ul style="list-style-type: none">➤ Bazedoxifene, lasofoxifene, ospemifene and raloxifene are classified here.
G03X	OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM <ul style="list-style-type: none">➤ Tibolone is classified in G03D C.➤ Bazedoxifene, lasofoxifen, raloxifene, and ospemifene are classified here.➤ All plain cyproterone preparations (and combinations of cyproterone and estrogen) regardless of indication are classified in G03H.➤ Ulipristal for emergency contraception is classified in G03A D.	G03X	OTHER SEX HORMONES AND SIMILAR PRODUCTS <ul style="list-style-type: none">➤ Tibolone is classified here➤ Products containing cyproterone are classified according to indication.➤ Combinations of estrogen and cyproterone are classified in D10B (DIANE 35) and G3F (CLIMEN).➤ Bazedoxifene, lasofoxifen, raloxifene, and ospemifene are classified in G3J.➤ Plain cyproterone preparations are classified here and in L2B depending on indication.

WHO (Substance based)

EphMRA (Product based)

-
- Mifepristone is classified here.

- Ulipristal is also classified in G3A6 when indicated for emergency contraception.
 - Mifepristone is also classified in G3A6 when indicated for emergency contraception.
-

G04 UROLOGICALS



- Urinary quinolones are in J01M.
- Other urinary antibacterials are in J01X.

G4 UROLOGICALS

G4A URINARY ANTI-INFECTIVES AND ANTISEPTICS

- Urinary quinolones are here in G4A2.
 - Halogenated quinolones are in G4E.
 - Other antiseptics and anti-bacterials are here in G4A9.
-

G04B UROLOGICALS

- Drugs used in erectile dysfunction are here in G04B E.
- Urinary antispasmodics are here in G04B D.



- Other urologicals are in G4X with exceptions below.
 - Erectile dysfunction products are in G4E.
 - Urinary incontinence products are in G4D.
-

G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY

- Indoramin is classified in C02CA.

G4C BPH (BENIGN PROSTATIC HYPERTROPHY) PRODUCTS

- Indoramin when indicated for BPH or hypertension is classified in C2A2.
 - Indoramin when indicated for migraine is classified in N2C9.
-



G4D URINARY INCONTINENCE PRODUCTS



- Phentolamine used as an antidote is in V03A. It is only in G04B for erectile dysfunction when in combinations.
- PDE5 inhibitors are classified in G04BE.

G4E ERECTILE DYSFUNCTION PRODUCTS

- Phentolamine for erectile dysfunction is here. It is in V3X when used as an antidote.
 - PDE5 inhibitors when indicated only for PAH are classified in C6A.
-



- Other urologicals are in G04B.

G4X ALL OTHER UROLOGICAL PRODUCTS

WHO (Substance based)

EphMRA (Product based)

H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

The classification of these hormonal products is based according to the origin of the hormones and not according to their indication.

H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES



H01A ANTERIOR PITUITARY LOBE HORMONES and ANALOGUES

H01A A ACTH

H01A B Thyrotropin

H01A C Somatropin and somatropin agonists



H01A X Other anterior pituitary lobe hormones and analogues

➤ Pegvisomant is classified here.

H01B POSTERIOR PITUITARY LOBE HORMONES

H01B A Vasopressin and analogues

➤ Terlipressin is classified here.

H01B B Oxytocin and analogues

H01C HYPOTHALAMIC HORMONES

H01C A Gonadotrophin-releasing hormones

➤ Histrelin is classified in L02A E

H SYSTEMIC HORMONAL PREPARATIONS (EXCL. SEX HORMONES)

H1 PITUITARY AND HYPOTHALAMIC HORMONES

H1A ACTH

Included in H3A THYROID PREPARATIONS

H4C GROWTH HORMONES



➤ Pegvisomant is classified in H1C.



H4D ANTIDIURETIC HORMONES

➤ Terlipressin is classified in B2G.

G2A LABOUR INDUCERS

H1C HYPOTHALAMIC HORMONES

H1C1 GONADOTROPHIN RELEASING HORMONES

➤ Histrelin is classified here and in L2A3.

WHO (Substance based)

EphMRA (Product based)

H01C B	Somatostatin and analogues	H1C2	ANTIGROWTH HORMONES ➤ Pegvisomant is classified here.
H01C C	ANTI-GONADOTROPHIN-RELEASING HORMONES	H1C3	ANTIGONADOTROPHIN-RELEASING HORMONES
H02	CORTICOSTEROIDS FOR SYSTEMIC USE	H2	SYSTEMIC CORTICOSTEROIDS
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	H2A	SYSTEMIC CORTICOSTEROIDS, PLAIN
H02B	CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS	H2B	SYSTEMIC CORTICOSTEROID COMBINATIONS
H02C	ANTIADRENAL PREPARATIONS ➤ Trilostane is classified here.	❖	➤ Trilostane is classified in H4X.
H03	THYROID THERAPY	H3	THYROID THERAPY
H03A	THYROID PREPARATIONS ➤ Thyrotrophin is classified in H01A.	H3A	THYROID PREPARATIONS ➤ Thyrotrophin is classified here.
H03B	ANTITHYROID PREPARATIONS	H3B	ANTI-THYROID PREPARATIONS
H03C	IODINE THERAPY	H3C	IODINE THERAPY
H04	PANCREATIC HORMONES	❖	
H04A	GLYCOGENOLYTIC HORMONES	H4B	GLUCAGON
H05	CALCIUM HOMEOSTASIS	❖	
H05A	PARATHYROID HORMONES AND ANALOGUES	H4E	PARATHYROID HORMONES AND ANALOGUES
H05B	ANTI-PARATHYROID HORMONES	❖	

WHO (Substance based)

EphMRA (Product based)

H05B A Calcitonin preparations

H4A CALCITONINS

H05B X Other anti-parathyroid agents

H4F ANTIPARATHYROID PRODUCTS

WHO (Substance based)

EphMRA (Product based)

J ANTIINFECTIVES FOR SYSTEMIC USE

J01 ANTIBACTERIALS FOR SYSTEMIC USE

J01A TETRACYCLINES

- Tigecycline is classified here.

J01B AMPHENICOLS

J01C BETA-LACTAM ANTIBACTERIALS, PENICILLINS

J01D OTHER BETA LACTAM ANTIBACTERIALS

- J01D B-E
- First-fourth generation cephalosporins.
 - Loracarbef is classified here in J01D C.
 - Other cephalosporins (including ceftobiprole medocaril and ceftaroline fosamil) are classified in J01D I.

J01D F Monobactams

J01D H Carbapenems

+

J01D I Other cephalosporins and penems

J01E SULFONAMIDES AND TRIMETHOPRIM

J GENERAL ANTI-INFECTIVES SYSTEMIC

J1 SYSTEMIC ANTIBACTERIALS

J1A TETRACYCLINES AND COMBINATIONS

- Tigecycline is classified in J1X.

J1B CHLORAMPHENICOL AND COMBINATIONS

J1C BROAD SPECTRUM PENICILLINS

+

J1H MEDIUM AND NARROW SPECTRUM PENICILLINS

+

J1L CARBENICILLIN AND SIMILAR TYPES

❖

J1D CEPHALOSPORINS

- J1D1-2
- Oral – injectable cephalosporins.
 - Loracarbef is classified in J1P3.
 - Other cephalosporins (including ceftobiprole medocaril and ceftaroline fosamil) are classified here.

J1P1 Monobactams

J1P2 Penems and carbapenems

- Other cephalosporins (including ceftobiprole medocaril and ceftaroline fosamil) are classified in J1D.

J1E TRIMETHOPRIM AND SIMILAR FORMULATIONS

+

WHO (Substance based)

EphMRA (Product based)

		J3A	SYSTEMIC SULFONAMIDES
J01F	MACROLIDES, LINCOSAMIDES and STREPTOGRAMINS ➤ Pristinamycin is classified here.	J1F	MACROLIDES AND SIMILAR TYPES ➤ Pristinamycin is classified in J1X.
J01G	AMINOGLYCOSIDE ANTIBACTERIALS ➤ Plain streptomycin is classified here.	J1K	AMINOGLYCOSIDES ➤ Streptomycin is classified in J1X.
J01M	QUINOLONE ANTIBACTERIALS	J1G	FLUOROQUINOLONES ➤ Non-halogenated quinolones are in G4A2.
J01R	COMBINATIONS OF ANTIBACTERIALS Sulfonamides, combinations with other antibacterials (excl. trimethoprim) are classified here.	❖	Combinations of antibacterials are classified based on classification hierarchy. See guidelines for details. Sulfonamides in combinations with other antibacterials (excl. trimethoprim) are classified in J3A.
❖	➤ Monobactams, carbapenems, carbacephems are classified in J01D.	J1P	OTHER BETA-LACTAM ANTIBACTERIALS, EXCLUDING PENICILLINS, CEPHALOSPORINS ➤ Monobactams, carbapenems, carbacephems are classified here.
J01X	OTHER ANTIBACTERIALS ➤ Pristinamycin is classified J01F ; Tigecyclin is in J01A. ➤ Parenteral imidazole formulations are classified here in J01X D.	J1X	OTHER ANTIBACTERIALS ➤ Pristinamycin and tigecyclin are classified here. ➤ Parenteral imidazole formulations are classified in J8B.
J02	ANTIMYCOTICS FOR SYSTEMIC USE	J2	SYSTEMIC AGENTS FOR FUNGAL INFECTIONS
J02A	ANTIMYCOTICS FOR SYSTEMIC USE ➤ Terbinafine and griseofulvin are classified in D01B.	J2A	SYSTEMIC AGENTS FOR FUNGAL INFECTIONS ➤ Terbinafine for systemic use is classified here. ➤ Griseofulvin is classified in D1A2.

WHO (Substance based)

EphMRA (Product based)

❖		J3	SYSTEMIC SULPHONAMIDES
	<ul style="list-style-type: none">➤ All plain sulphonamides are classified in J01E. Sulfonamides, combinations with other antibacterials (excl. trimethoprim) are classified in J01R.		<ul style="list-style-type: none">➤ This group includes plain sulphonamides and sulphonamide/antibiotic combinations, excl trimethoprim/sulphonamides which are classified J1E.
❖		J3	SYSTEMIC SULPHONAMIDES
J04	ANTIMYCOBACTERIALS	J4	ANTIMYCOBACTERIALS
J04A	DRUGS FOR TREATMENT OF TUBERCULOSIS <ul style="list-style-type: none">➤ Rifampicin and rifamycin are classified here.➤ Plain streptomycin is classified in J01G A.	J4A	ANTITUBERCULAR PRODUCTS <ul style="list-style-type: none">➤ Rifampicin and rifamycin are classified here and in J1M.➤ Streptomycin is classified here.
J04B	DRUGS FOR TREATMENT OF LEPROSY <ul style="list-style-type: none">➤ Thalidomide, also when used for leprosy, is classified L04A X.	J4B	DRUGS FOR THE TREATMENT OF LEPROSY <ul style="list-style-type: none">➤ Thalidomide, when used for leprosy is classified here, otherwise it is classified in L4.
J05	ANTIVIRALS FOR SYSTEMIC USE	J5	ANTIVIRALS FOR SYSTEMIC USE
J05A	DIRECT ACTING ANTIVIRALS <ul style="list-style-type: none">➤ The combination of ribavirin and peginterferon is classified in L03A.➤ Antivirals acting against HIV are classified here in J05A E–J05A G, and J05A X depending on inhibition mechanism. HIV combination products are classified in J05AR.➤ Cobicistat is classified in V03AX.	J5B	ANTIVIRALS, EXCLUDING ANTI-HIV PRODUCTS <ul style="list-style-type: none">➤ The combination of ribavirin and peginterferon is classified here.
		+	
		J5C	HIV ANTIVIRALS <ul style="list-style-type: none">➤ HIV antivirals are classified here in J5C1 – J5C5 depending on inhibition mechanism. Combinations of different classes of HIV antivirals are classified in J5C9.➤ Cobicistat is classified here.
J06	IMMUNE SERA AND IMMUNOGLOBULINS	J6	SERA AND GAMMA-GLOBULIN

WHO (Substance based)

EphMRA (Product based)

J06A	IMMUNE SERA	J6A	ANTITOXIC SERA
J06B	IMMUNOGLOBULINS	J6C	POLYVALENT IMMUNO-GLOBULINS - INTRAVENOUS
		+	
		J6D	HOMOLOGOUS IMMUNOLOGICALLY ACTIVE GLOBULINS - INTRAVENOUS
		+	
		J6E	POLYVALENT IMMUNO-GLOBULINS - INTRAMUSCULAR
		+	
		J6F	POLYVALENT IMMUNO-GLOBULINS – COMBINATION MODULATION - MAINLY INTRAMUSCULAR
		+	
		J6G	SPECIFIC IMMUNOGLOBULINS - ANTIBACTERIAL
		+	
		J6H	SPECIFIC IMMUNOGLOBULINS - ANTIVIRAL
		+	
		J6J	OTHER SPECIFIC IMMUNOGLOBULINS
J07	VACCINES	J7	VACCINES
J07A	BACTERIAL VACCINES	J7D	BACTERIAL VACCINES
	➤ Also includes combinations of bacterial vaccines.		➤ Includes vaccines against one bacterial group. All combinations acting against more than one group of virus or bacteria are classified in J7B.
J07B	VIRAL VACCINES	J7E	VIRAL VACCINES
	➤ Also includes combinations of viral vaccines.		

WHO (Substance based)

EphMRA (Product based)

			➤ Includes vaccines against one viral group. All combinations acting against more than one group of virus or bacteria are classified in J7B.
J07C	BACTERIAL AND VIRAL VACCINES, COMBINED	J7B	COMBINATIONS OF VACCINES
	➤ Bacterial vaccines combinations and viral vaccines combination are classified J07A and J07B respectively.		➤ All combinations of bacterial and viral vaccines are classified here.
J07X	OTHER VACCINES	J7X	ALL OTHER VACCINE —LIKE PRODUCTS
❖		J8	OTHER ANTI-INFECTIVES
	➤ Parenteral imidazole formulations are classified in J01X D.		➤ Parenteral imidazole formulations are classified here in J8B.

WHO (Substance based)

EphMRA (Product based)

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

L01 ANTINEOPLASTIC AGENTS

L01A ALKYLATING AGENTS

- Altretamine is classified in L01X.

L01B ANTIMETABOLITES

- Methotrexate is classified in L01B and L04A.

L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS

- Irinotecan and topotecan are classified in L01X X.
- Products for cancer containing omacetaxine mepisuccinate are classified in L01X X

L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES

- Gemtuzumab ozogamicin is classified in L01X.

L01X OTHER ANTINEOPLASTIC AGENTS

- Altretamine is classified here.
- Alitretinoin is classified in D11A.
- Irinotecan and topotecan are classified here in L01X X.
- Ibritumomab tiuxetan, tositumomab and iodine (131I) tositumomab are classified in V10X.

L01X A Platinum compounds

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

L1 CYTOSTATICS

L1A ALKYLATING AGENTS

- Altretamine is classified here.

L1B ANTIMETABOLITES

- Methotrexate is classified in D5B, M1C and L01B.

L1C PLANT-BASED ANTINEOPLASTICS

- Irinotecan and topotecan are classified here.
- Products for cancer containing omacetaxine mepisuccinate are classified here.

L1D CYTOSTATIC ANTINEOPLASTICS

- Gemtuzumab ozogamicin is classified here.

L1X ALL OTHER ANTINEOPLASTICS

- Altretamine is classified in L1A.
- Irinotecan and topotecan are classified in L1C.
- Ibritumomab tiuxetan, tositumomab and iodine (131I) tositumomab are classified here.

L1F PLATINUM ANTINEOPLASTICS

WHO (Substance based)

EphMRA (Product based)

L01X B	Methylhydrazines	L1X9	All other antineoplastics
L01X C	Monoclonal Antibodies <ul style="list-style-type: none">➤ Gemtuzumab is classified here.➤ Alemtuzumab is classified in L04A A.	L1G	MONOCLONAL ANTIBODY ANTINEPLASTICS <ul style="list-style-type: none">➤ Gemtuzumab ozogamicin is classified in L1D.➤ Alemtuzumab is also classified in N7X.
L01X D	Agents used in photodynamic therapy	❖	➤ These products are classified in L1X9
L01X E	Protein kinase inhibitors	L1H	PROTEIN KINASE INHIBITOR ANTINEOPLASTICS
L01X X	Other antineoplastic agents <ul style="list-style-type: none">➤ Sipuleucel-T is classified in L03X A.➤ Aflibercept for metastatic colorectal cancer is classified here and for macular degeneration is classified in S01L; and c. Products for cancer containing omacetaxine mepisuccinate are classified here.	L1X1 + L1X9	Adjuvant preparations for cancer therapy <ul style="list-style-type: none">➤ Alitretinoin is classified here when indicated to treat cutaneous lesions in Kaposi's sarcoma and in D5X when indicated for the treatment of eczema. All other antineoplastics <ul style="list-style-type: none">➤ Sipuleucel-T is classified here.➤ Aflibercept is classified here and in S1P.➤ Products for cancer containing omacetaxine mepisuccinate are classified in L1C.

L02 ENDOCRINE THERAPY

L02A	HORMONES AND RELATED AGENTS
L02A A	Estrogens
L02A B	Progestogens
L02A E	Gonadotrophin releasing hormone analogues <ul style="list-style-type: none">➤ Histrelin is classified here.

L2 CYTOSTATIC HORMONE THERAPY

L2A	CYTOSTATIC HORMONES
L2A1	Cytostatic oestrogens
L2A2	Cytostatic progestogens
L2A3	Cytostatic gonadotrophin releasing hormone analogues <ul style="list-style-type: none">➤ Histrelin is classified here and in H1C1.

WHO (Substance based)

EphMRA (Product based)

L02A X	Other Hormones	L2A9	Other cytostatic hormones
L02B	HORMONE ANTAGONISTS AND RELATED AGENTS	L2B	CYTOSTATIC HORMONE ANTAGONISTS
L02B A	Anti-estrogens <ul style="list-style-type: none">➤ Fulvestrant is classified here.	L2B1	Cytostatic anti-estrogens <ul style="list-style-type: none">➤ Fulvestrant is classified in L2B9.
L02B B	Anti-androgens <ul style="list-style-type: none">➤ All plain cyproterone preparations (and combinations of cyproterone and estrogen) regardless of indication are classified here.➤ Abiraterone is classified in L02B X.	L2B2	Cytostatic anti-androgens <ul style="list-style-type: none">➤ Plain cyproterone preparations are classified here and in G3X depending on indication.➤ Abiraterone is classified here.
L02B G	Aromatase inhibitors	L2B3	Cytostatic aromatase inhibitors
L02B X	Other hormone antagonists and related agents <ul style="list-style-type: none">➤ Abiraterone is classified here.➤ Fulvestrant is classified in L02B A.	L2B9	Other cytostatic hormone antagonists <ul style="list-style-type: none">➤ Abiraterone is classified in L2B2.➤ Fulvestrant is classified here.

L03 IMMUNOSTIMULANTS

L03A IMMUNOSTIMULANTS

- Levamisole is classified in P02C E.

L03A A Colony stimulating factors

L03A C + Interleukins +

L3 IMMUNOMODULATING AGENTS

L3A IMMUNOSTIMULATING AGENTS, EXCL. INTERFERONS

- Levamisole, when indicated as immunostimulant, is classified here.

L3A1 COLONY STIMULATING FACTORS

L3A9 All other immunostimulating agents excluding interferons

WHO (Substance based)

EphMRA (Product based)

L03A X Other cytokines and immunomodulators
➤ Sipuleucel-T is classified here.

➤ Sipuleucel-T is classified in L1X9.

L03A B INTERFERONS

L3B INTERFERONS

➤ Interferons indicated for viral hepatitis only are classified in J5B

L04 IMMUNOSUPPRESSANTS

L4 IMMUNOSUPPRESSIVE AGENTS

L04A IMMUNOSUPPRESSANTS

+

L04A A Selective immunosuppressants
➤ Alefacept is classified here.
➤ Abatacept, alemtuzumab, apremilast, leflunomide, tocilizumab are classified here.
➤ Vedolizumab is classified here.
➤ Fingolimod is classified here.

❖
Included in L4X
➤ Alefacept is classified in D5B.
➤ Abatacept, apremilast, leflunomide and tocilizumab are classified in M1C.
➤ Alemtuzumab is classified in L1G and N7X.
➤ Vedolizumab is classified in A7E
➤ Fingolimod when indicated for multiple sclerosis only is classified in N7X.

L04A B TNF- α inhibitors

L4B ANTI-TNF PRODUCTS

L04A C Interleukin inhibitors
➤ Anakinra and ustekinumab are classified here

L4C INTERLEUKIN INHIBITORS
➤ Ustekinumab when indicated for psoriasis alone it is classified in D5B.

L04A D Calcineurin inhibitors

❖
➤ Anakinra is classified in M1C.
Calcineurin inhibitors when indicated for prevention of organ rejection are classified in L4X.

L04A X Other immunosuppressants

L4X OTHER IMMUNOSUPPRESSANTS

WHO (Substance based)

- Methotrexate is classified in L01B and L04A X.
- Thalidomide is classified in L04A X.

EphMRA (Product based)

- Methotrexate is classified in D5B, M1C and L01B.
 - Thalidomide, when used for lepra is classified in J4B, otherwise it is classified here.
-
-

WHO (Substance based)

EphMRA (Product based)

M	MUSCULO-SKELETAL SYSTEM	M	MUSCULO-SKELETAL SYSTEM
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	M1	ANTIINFLAMMATORY AND ANTI-RHEUMATIC PRODUCTS
M01A	ANTIINFLAMMATORY and ANTIRHEUMATIC PRODUCTS, NON STEROIDS <ul style="list-style-type: none">➤ This group comprises antiinflammatory preparations for systemic use, regardless of strength.➤ Mefenamic acid is classified here.➤ Ketorolac is classified here.➤ Chondroitin, Diacerein and Glucosamine are classified here.	M1A	ANTI-RHEUMATIC, NON STEROIDAL <ul style="list-style-type: none">➤ Anti-inflammatory analgesics used for both musculo-skeletal conditions and analgesia are classified in M1A. Those that are indicated mainly for general pains are in N2B.➤ Mefenamic acid is classified in N2B.➤ Ketorolac is classified in N2B.➤ Chondroitin, Diacerein and Glucosamine are classified in M5X.
M01B	ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION		
M01B A	Antiinflammatory/antirheumatic agents in combination with corticosteroids	M1B	ANTI-RHEUMATIC CORTICOSTEROID COMBINATIONS
M01C	SPECIFIC ANTIRHEUMATIC AGENTS <ul style="list-style-type: none">➤ Chloroquine is classified in P01B.➤ Anakinra, abatacept, apremilast, leflunomide and tocilizumab are classified in L04A.➤ Methotrexate is classified in L01B and L04A.	M1C	SPECIFIC ANTI-RHEUMATIC AGENTS <ul style="list-style-type: none">➤ Chloroquine is classified here and in P1D.➤ Anakinra, abatacept, apremilast, leflunomide and tocilizumab are classified here.➤ Methotrexate is classified in D5B, M1C and L01B.
M02	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	M2	TOPICAL ANTI-RHEUMATICS AND ANALGESICS
M02A	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN <ul style="list-style-type: none">➤ Bendazac is classified here.	M2A	TOPICAL ANTI-RHEUMATICS AND ANALGESICS <ul style="list-style-type: none">➤ Bendazac is classified in D3A.

WHO (Substance based)

- Bufexamac is classified here.
- Chymotrypsin is classified in B06A A when used as haematological enzymes.
- Tolperisone is classified here.

EphMRA (Product based)

- Bufexamac is also classified in D4A.
- Nimesulide in throat preparations is also classified in R2A.
- Chymotrypsin is classified here or in A9A, C5B, D3A and V3H depending on indications.
- Tolperisone is classified in M3B.

M03	MUSCLE RELAXANTS	M3	MUSCLE RELAXANTS
M03A	MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS <ul style="list-style-type: none">➤ Dantrolene is classified in M03C.	M3A	MUSCLE RELAXANTS, PERIPHERALLY ACTING <ul style="list-style-type: none">➤ Dantrolene is classified here.
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS	M3B	MUSCLE RELAXANTS, CENTRALLY ACTING <ul style="list-style-type: none">Tolperisone is classified here.
M03C	MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS <ul style="list-style-type: none">➤ Dantrolene is classified here.	❖	➤ Dantrolene is classified in M3A.
M04	ANTI-GOUT PREPARATIONS	M4	ANTI-GOUT PREPARATIONS
M04A	ANTI-GOUT PREPARATIONS	M4A	ANTI-GOUT PREPARATIONS
M5	DRUGS FOR TREATMENT OF BONE DISEASES	M5	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M05B	DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION <ul style="list-style-type: none">➤ Eptotermin alfa is classified here.➤ Dibotermin alfa is classified here.	M5B	BONE CALCIUM REGULATORS <ul style="list-style-type: none">➤ Eptotermin alfa is classified in M5X.➤ Dibotermin alfa is classified in M5X.
M09	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	❖	
M09A			

WHO (Substance based)

EphMRA (Product based)

OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM

M09A A Quinine and DERIVATES

+

M09A X Other drugs for disorders of the Musculo-skeletal system

- Eptotermin alfa is classified in M05B.
- Dibotermin alfa is classified in M05B

M09A B Enzymes

- Bromelains is classified in B06A A.
- Chymotrypsin and trypsin are classified in B06A A when used as haematological enzymes.

Included in
M5X ALL OTHER MUSCULOSKELETAL PRODUCTS

- Eptotermin alfa is classified here.
- Dibotermin alfa is classified here.

V3H ANTI INFLAMMATORY ENZYMES

- Bromelains is classified here or, in A9A and D3A depending on indications.
 - Chymotrypsin is classified here or in A9A, C5B, D3A and M2A depending on indications.
-

WHO (Substance based)

EphMRA (Product based)

N	NERVOUS SYSTEM	N	CENTRAL NERVOUS SYSTEM
N01	ANESTHETICS	N1	ANAESTHETICS
N01A	ANESTHETICS, GENERAL <ul style="list-style-type: none">➤ Droperidol is classified in N5A.	N1A	ANAESTHETICS, GENERAL <ul style="list-style-type: none">➤ Phenoperidine and anileridine are classified in N2A.➤ Droperidol is classified here or in N2A or N5A.
N01B	ANESTHETICS, LOCAL <ul style="list-style-type: none">➤ Capsicum for neuropathic pain is classified here, otherwise it is in M02A.	N1B	ANAESTHETIC LOCAL <ul style="list-style-type: none">➤ Topical capsicum is classified in M2A or, when used for neuropathic pain, in N7X.
N02	ANALGESICS	N2	ANALGESICS
➡	<ul style="list-style-type: none">➤ All antiinflammatory products are classified in M01A, regardless of strength.➤ Analgesic/cold preparations are classified here intended for use as pain relief.➤ Analgesics indicated for dysmenorrhea are classified here.		<ul style="list-style-type: none">➤ Anti-inflammatory analgesics used for both musculo-skeletal conditions and analgesia are classified in M01A. Those that are indicated mainly for general pains are in N2B.➤ Analgesic/cold preparations are classified in R5A.➤ Products specifically indicated for dysmenorrhea are classified in G2X1.
N02A	OPIOIDS <ul style="list-style-type: none">➡➤ This classification is based solely on substances, not on legal status.➤ Dihydrocodeine is classified here.➤ Droperidol is classified in N5A.	N2A	NARCOTICS <ul style="list-style-type: none">➤ Includes all analgesics classified as narcotics in accordance with the <u>legal definition of narcotic analgesics in each country</u>.➤ Dihydrocodeine is classified in N2B.➤ Droperidol is classified here, or in N1A or N5A.
N02B	OTHER ANALGESICS AND ANTIPYRETICS <ul style="list-style-type: none">➡➤ Cannabinoids (cannabidiol and tetrahydrocannabinol) are classified here.	N2B	NON-NARCOTICS AND ANTI-PYRETICS <ul style="list-style-type: none">➤ Cannabinoids (cannabidiol and tetrahydrocannabinol), used for refractory spasticity, are classified in N7X.

WHO (Substance based)

EphMRA (Product based)

- N02C** **ANTIMIGRAINE PREPARATIONS**
- Dihydroergotamine which is also used in the treatment of hypotension, is classified in this group.
 - Pizotifen is classified here.
 - Lisuride (low dose) is classified here and in G02C (high dose).
 - Flumedroxone is classified here.
 - Indoramin is classified in C02.

- N2C** **ANTI MIGRAINE PREPARATIONS**
- Dihydroergotamine is classified here and also in C1C1.
 - Pizotifen is classified here and in A15.
 - Lisuride is classified in N4A.
 - Flumedroxone is classified in G3D.
 - Indoramin is classified here and in C2.

N03 **ANTIEPILEPTICS**

N3 **ANTI-EPILEPTICS**

N03A ANTIEPILEPTICS

N3A ANTI-EPILEPTICS

N04 **ANTI-PARKINSON DRUGS**

N4 **ANTI-PARKINSON DRUGS**

N04A ANTICHOLINERGIC AGENTS

+

N04B DOPAMINERGIC AGENTS

- Lisuride is classified in N02C and in G02C.

- Lisuride is classified here.

N05 **PSYCHOLEPTICS**

N5 **PSYCHOLEPTICS**

The group is divided into therapeutic subgroups:

N05A – Antipsychotics

➤ N05B – Anxiolytics

➤ N05C – Hypnotics and sedatives

The group is divided into therapeutic subgroups:

N5A – Antipsychotics

➤ N5B – Hypnotic/Sedatives

➤ N5C – Tranquilizers

N05A ANTIPSYCHOTICS

- Lithium is classified here.
- Droperidol is classified here.

N5A ANTIPSYCHOTICS

- Lithium is classified in N6A.
 - Droperidol is classified here, or in N1A or N2A.
-

WHO (Substance based)

EphMRA (Product based)

- N05B ANXIOLYTICS
- Mebutamate is classified here.
 - Mefenoxalone is classified here.

- N05C HYPNOTICS AND SEDATIVES
- Melatonin is classified here.

N06 PSYCHOANALEPTICS

- N06A ANTIDEPRESSANTS
- Lithium is classified in N05A.
 - Ademetionine is in A16A.
 - Bupropion is classified here.

- N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
- Dexamfetamine and metamfetamine are classified here.
 - Caffeine is classified here.
 - Citicoline is classified here.
 - Atomoxetine is classified here.
 - Mebicar is classified here.

- N5C TRANQUILLISERS
- Mebutamate is classified in C2A.
 - Metenoxalone is classified in M3B.
 - Mebicar is classified here.

- N5B HYPNOTICS / SEDATIVES
- Melatonin (plain) indicated for sleep rhythm disturbances is classified in H4X. Prolonged-release melatonin indicated for primary insomnia is classified here.

N6 PSYCHOANALEPTICS EXCL. ANTI-OBESITY PREPARATIONS

- N6A ANTI-DEPRESSANTS AND MOOD STABILISERS
- Lithium is classified here.
 - Ademetionine is classified here.
 - Bupropion is classified here and in N7B.

- N6B PSYCHOSTIMULANTS
- Dexamfetamine and metamfetamine are classified here and in A8.
 - Plain caffeine is classified in C1C1.
 - Citicoline is classified in C4A.
 - + ➤ Mebicar is classified in N5C.
 - Atomoxetine is classified in N7X.

- N6D NOOTROPICS
- Citicoline is classified in C4A.

- +
N6E NEUROTONICS AND OTHER MISCELLANEOUS PRODUCTS

WHO (Substance based)

EphMRA (Product based)

N06C PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION

N6C PSYCHOLEPTIC-PSYCHOANALEPTIC COMBINATIONS

N06D ANTI-DEMENTIA DRUGS

- Ipidacrine is classified here.

N7D ANTI-ALZHEIMER PRODUCTS

- Ipidacrine is classified in N7X.

N07 OTHER NERVOUS SYSTEM DRUG



N7 OTHER CNS DRUGS

N07A PARASYMPATHOMIMETICS

- Nalorphine, naltrexone, naloxone and flumazenil are classified in V03A.
- Cevimeline is classified here.
- Alemtuzumab is classified in L04A A.



OTHER CNS DRUGS

Included in
N7X

- Nalorphine, naltrexone, naloxone, flumazenil, and ipidacrine are classified in N7X.
- Cevimeline is classified in A01A.
- Alemtuzumab when indicated for multiple sclerosis is classified here.

N07B DRUGS USED IN ADDICTIVE DISORDERS

N07B A Drugs used in nicotine dependence

- Bupropion is classified in N6A.

N7B ANTISMOKING PRODUCTS

- Bupropion is classified here and in N6A (antidepressant).

N07B B Drugs used in alcohol dependence

- Nalmefene is classified here.

N7E DRUGS USED IN ALCOHOL DEPENDENCE

- Nalmefene is also classified in N7X.

N07B C Drugs used in opioid dependence

N7F DRUGS USED IN OPIOID DEPENDENCE

N07C ANTIVERTIGO PREPARATIONS

N7C ANTIVERTIGO PREPARATIONS

N07X OTHER NERVOUS SYSTEM DRUGS

- Sugammadex is classified in V03A B here.

N7X ALL OTHER CNS DRUGS

- Sugammadex is classified here.
-

WHO (Substance based)



- Topical capsicum, when used for neuropathic pain, is classified in N01B.
- Cannabinoids (cannabidiol and tetrahydrocannabinol) are classified in N02B.
- Alemtuzumab, fingolimod or terflunomide are classified L04AA.

EphMRA (Product based)

- Topical capsicum, when used for neuropathic pain, is classified here.
- Cannabinoids (cannabidiol and tetrahydrocannabinol) are classified here.
- Ipidacrine is classified here.
- Alemtuzumab, fingolimod or terflunomide when indicated for multiple sclerosis only are classified here.
- Nalmefene is also classified in N7E.

WHO (Substance based)

EphMRA (Product based)

P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

This group is subdivided according to types of parasites

P01 ANTIPROTOZOALS



P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES

- Systemic metronidazole is classified here and in J01X D.
- Clioquinol, chlorquinaldol, tilbroquinol and glycobriarsol are classified here.

P01B ANTI-MALARIALS

- Chloroquine and hydroxychloroquine are classified here.

P01C AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS



P02 ANTHELMINTICS



The anthelmintics are subdivided according to the main type of worms (i.e. trematodes, nematodes and cestodes) causing the infections.

- Levamisole is classified here.
- Ivermectin is classified in here and in D11A.

P PARASITOLOGY

P1 ANTI-PARASITIC PRODUCTS



P1A AMOEBICIDES

- Nitroimidazole derivatives are classified either in G1A or J8B.
- Clioquinol, chlorquinaldol, tribroquinol and glycobriarsol are classified in A7A.

P1D ANTI-MALARIALS

- Chloroquine and hydroxychloroquine are classified here and in M1C.

P1G OTHER ANTI-PARASITIC AGENTS

P1C SCHISTOSOMICIDES



+

P1B ANTHELMINTICS, EXCL. SCHISTOSOMICIDES

- Levamisole is classified here in L3A.
- Ivermectin is classified in here and in P3A, depending on indication.

WHO (Substance based)

EphMRA (Product based)

P03 **ECTOPARASITICIDES, INCL. SCABICIDES,
INSECTISIDES AND REPELLENTS**

P3 **ECTOPARASITICIDES, INCL. SCABICIDES, INSECTISIDES
AND REPELLENTS**

P03A ECTOPARASITICIDES, INCL. SCABICIDES

- Ivermectin is classified in P02C and D11A.

P3A ECTOPARASITICIDES, incl. SCABICIDES

- Ivermectin is classified here and in P1B, depending on indication.

P03B INSECTICIDES AND REPELLENTS

- Dimethylphthalate is classified here.

P3B INSECTICIDES AND REPELLENTS

- Dimethylphthalate is classified in D4A.
-

WHO (Substance based)

EphMRA (Product based)

R **RESPIRATORY SYSTEM**

R01 **NASAL PREPARATIONS**

R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS
FOR TOPICAL USE

R01B NASAL DECONGESTANTS FOR SYSTEMIC USE

R02 **THROAT PREPARATIONS**

R02A THROAT PREPARATIONS

- Preparations for the treatment of throat infections (lozenges for common cold condition) are classified here.

R03 **DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES**

This group is harmonized on the second level.

- Alfa 1 antitrypsin (alpha-1-proteinase inhibitor) is classified in B02A.
- Azelastine is classified in R06A.
- Ketotifen is classified in R06A.
- Terfenadine is classified in R06A.



R **RESPIRATORY SYSTEM**

R1 **NASAL PREPARATIONS**

R01A TOPICAL NASAL PREPARATIONS

R1B SYSTEMIC NASAL PREPARATIONS

R2 **THROAT PREPARATIONS**

R2A THROAT PREPARATIONS

- Products indicated for both the posterior part of the mouth and throat infections are classified in R2A or A1A depending on the main indication.
- Nimesulide in throat preparations is also here.

R3 **ANTI-ASTHMA AND COPD PRODUCTS**

- Alpha-1-proteinase inhibitor (alfa 1 antitrypsin) is classified here.
- Azelastine is classified here.
- Ketotifen is classified here.
- Terfenadine (Japan only) is classified here, in all other countries in R6A.

R4 **CHEST RUBS AND OTHER INHALANTS**

WHO (Substance based)

EphMRA (Product based)

R05	COUGH AND COLD PREPARATIONS	R5	COUGH AND COLD PREPARATIONS
➡	<ul style="list-style-type: none">➤ Cold preparations with therapeutic levels of antiinfectives should be classified in ATC group J – Antiinfectives for systemic use.➤ Cold preparations with therapeutic levels of analgesics/antiinflammatory agents should be classified in the respective N02/M01 groups.		<ul style="list-style-type: none">➤ COUGH/COLD PREPARATIONS WITH ANTI-INFECTIVES (R5B)➤ COLD PREPARATIONS WITHOUT ANTI-INFECTIVES (R5A)
R05C	EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS	R5C	EXPECTORANTS
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS	R5D	ANTITUSSIVES
	<ul style="list-style-type: none">➤ Cough suppressants with expectorants are in R05F.		<ul style="list-style-type: none">➤ Cough suppressants combination preparations are here in R5D2.
+			
R05F	COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS	R5F	OTHER COUGH AND COLD PREPARATIONS
			<ul style="list-style-type: none">➤ This group includes combinations without clearly expectorating or antitussive effect, expectorant teas and lozenges / medical sweets for cough.
R05X	OTHER COLD PREPARATIONS	❖	
R06	ANTIHISTAMINES FOR SYSTEMIC USE	R6	SYSTEMIC ANTIHISTAMINES
R06A	ANTIHISTAMINES FOR SYSTEMIC USE	R6A	SYSTEMIC ANTIHISTAMINES
	<ul style="list-style-type: none">➤ Antihistamines for systemic use are classified here.➤ Cyproheptadine is classified here.➤ Thiethylperazine is classified here.➤ Azelastine and ketotifen are classified here.		<ul style="list-style-type: none">➤ Antihistamines used in motion sickness are classified in A4A.➤ Cyproheptadine is also classified in A15.➤ Thiethylperazine is classified in A4A.➤ Azelastine and ketotifen are classified in R3C.
R07	OTHER RESPIRATORY SYSTEM PRODUCTS	R7	OTHER RESPIRATORY SYSTEM PRODUCTS

WHO (Substance based)

EphMRA (Product based)

R07A OTHER RESPIRATORY SYSTEM PRODUCTS

R07A A LUNG SURFACTANTS

R07A B RESPIRATORY STIMULANTS

R07A X OTHER RESPIRATORY SYSTEM PRODUCTS

R7C LUNG SURFACTANTS

R7A RESPIRATORY STIMULANTS

R7X ALL OTHER RESPIRATORY SYSTEM PRODUCTS

WHO (Substance based)

EphMRA (Product based)

S	SENSORY ORGANS	S	SENSORY ORGANS
S01	OPHTHALMOLOGICALS	S1	OPHTHALMOLOGICALS
S01A	ANTIINFECTIVES	S1A	OPHTHALMOLOGICAL ANTI-INFECTIVES
S01A D	Antivirals	+	
		S1D	OPHTHALMOLOGICAL ANTIVIRAL AGENTS
S01B	ANTIINFLAMMATORY AGENTS	S1B	OPHTHALMOLOGICAL CORTICOSTEROIDS
S01B C	Antiinflammatory agents, non-steroids	+	
		S1R	OPHTHALMIC NONSTEROIDAL ANTIINFLAMMATORIES
S01C	ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION	S1C	OPHTHALMOLOGICAL ANTI-INFLAMMATORY/ANTIINFECTIVE COMBINATIONS
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS	S1E	MIOTICS AND ANTIGLAUCOMA PREPARATIONS
S01F	MYDRIATICS AND CYCLOPLEGICS	S1F	MYDRIATICS AND CYCLOPLEGICS
S01G	DECONGESTANTS AND ANTIALLERGICS	S1G	OCULAR ANTI-ALLERGICS, DECONGESTANTS, ANTISEPTICS
S01H	LOCAL ANESTHETICS	S1H	OPHTHALMOLOGICAL LOCAL ANESTHETICS
S01J	DIAGNOSTIC AGENTS	S1T	OPHTHALMOLOGICAL DIAGNOSTIC AGENTS
S01K	SURGICAL AIDS	S1S	OPHTHALMOLOGICAL SURGICAL AIDS
S1L	ANTINEOVASCULARISATION AGENTS	S1P	OCULAR ANTINEOVASCULARISATION PRODUCTS
	➤ Aflibercept for macular degeneration is classified here, and for metastatic colorectal cancer in L1X X		➤ Aflibercept is classified here and in L1X.

WHO (Substance based)**EphMRA (Product based)**

❖		S1K	ARTIFICIAL TEARS AND OCULAR LUBRICANTS
❖		S1L	PREPARATIONS FOR USE WITH CONTACT LENSES
❖		S1M	EYE TONICS and EYE VITAMINS
❖		S1N	PREPARATIONS TO PREVENT CATARACT AND ANTICATARACTOGENICS
S01X	OTHER OPHTHALMOLOGICALS	S1X	OTHER OPHTHALMOLOGICALS
S02	OTOLOGICALS	S2	OTOLOGICALS
S02A	ANTIINFECTIVES	S2A	OTIC ANTI-INFECTIVES
S02B	CORTICOSTEROIDS	S2B	OTIC CORTICOSTEROIDS
S02C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	S2C	OTIC CORTICOSTEROID/ANTIINFECTIVE COMBINATIONS
S02D	OTHER OTOLOGICALS	S2D	OTHER OTOLOGICALS
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS	S3	OPHTHALMOLOGICAL/OTOLOGICAL COMBINATIONS
S03A	ANTIINFECTIVES	S3A	EYE/EAR ANTI-INFECTIVES
S03B	CORTICOSTEROIDS	S3B	EYE/EAR CORTICOSTEROIDS
S03C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMB.	S3C	EYE/EAR CORTICOSTEROID/ANTI-INFECTIVE COMBI.

WHO (Substance based)

EphMRA (Product based)

S03D OTHER OPHTHALMOLOGICAL AND OTOLOGICAL
PREPARATIONS

S3D OTHER EYE/EAR COMBINATIONS

WHO (Substance based)

EphMRA (Product based)

V	VARIOUS	V	VARIOUS
V01	ALLERGENS	V1	ALLERGENS
V01A	ALLERGENS	V1A	ALLERGENS
V03	ALL OTHER THERAPEUTIC PRODUCTS	V3	ALL OTHER THERAPEUTIC PRODUCTS
V03A	ALL OTHER THERAPEUTIC PRODUCTS	V3A	❖
V03A B	ANTIDOTES <ul style="list-style-type: none">➤ Zinc acetate is classified in A16A.➤ Sugammadex is classified here.➤ Plain phentolamine as an antidote is classified here.➤ Idarucizumab is classified here.	V3E	ANTIDOTES <ul style="list-style-type: none">➤ Zinc acetate is classified here when indicated for Wilson's disease.➤ Sugammadex is classified in N7X.➤ Phentolamine for erectile dysfunction is in G4E.➤ Phentolamine when used as an antidote is classified in V3X.➤ Idarucizumab is classified in B2B9.
V03A C	IRON CHELATING AGENTS	V3F	IRON-CHELATING AGENTS
V03A E	DRUGS FOR THE TREATMENT OF HYPERKALEMIA AND HYPERPHOSPHATEMIA <ul style="list-style-type: none">➤ Colestilan is classified here.➤ Calcium acetate is classified here.➤ Other plain calcium products are classified in A12A.	V3G	HYPERKALAEMIA/HYPERPHOSPHATEMIA PRODUCTS <ul style="list-style-type: none">➤ Colestilan is also classified in C10A.➤ Calcium-containing products indicated for hyperphosphatemia and calcium deficiency are classified here.
V03A F	DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT	V3D	DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT
V03A G – V03A Z	<ul style="list-style-type: none">➤ Nalfurafine is classified in V03A X.➤ Phentolamine when used as an antidote/reversal agent is classified in V03A B.	V3X	ALL OTHER THERAPEUTIC PRODUCTS <ul style="list-style-type: none">➤ Nalfurafine is classified in D4A.➤ Phentolamine when used as an antidote is classified here.

WHO (Substance based)

- Trypsin is classified in B06A A when used as haematological enzymes.
- Cobicistat is classified in V03AX.

EphMRA (Product based)

- Trypsin is classified here or in A9A and V3H depending on indications.
- Cobicistat is classified in J5C9.

V04 **DIAGNOSTIC AGENTS**



T

DIAGNOSTIC AGENTS

WHO (Substance based)**EphMRA (Product based)**

V04B URINE TESTS

T2C PREGNANCY AND OVULATION TESTS

T2D1 Diabetes tests, urine

T2X1 All other diagnostic tests, urine

V04C OTHER DIAGNOSTIC AGENTS

T2X2 + All other diagnostic tests, blood

T2X9 All other diagnostic tests

V04C A Tests for diabetes

T2D2 + Diabetes tests, blood

T2D9 Diabetes tests, other



T3 DIAGNOSTIC EQUIPMENT AND ACCESSORIES

V06 GENERAL NUTRIENTS**V6 DIETETIC AGENTS**

V06A DIET FORMULATIONS FOR TREATMENT OF OBESITY

V6A SLIMMING PREPARATIONS

V06B PROTEIN SUPPLEMENTS

V6B PROTEIN SUPPLEMENTS

V06C INFANT FORMULAS

V6C INFANT FORMULAS

V06D OTHER NUTRIENTS

V6D OTHER NUTRIENTS

V07 ALL OTHER NON-THERAPEUTIC PRODUCTS**V7 ALL OTHER NON-THERAPEUTIC PRODUCTS**

V07A ALL OTHER NON-THERAPEUTIC PRODUCTS

V7A ALL OTHER NON-THERAPEUTIC PRODUCTS

V08 CONTRAST MEDIA

Classified in group T

V08A X-RAY CONTRAST MEDIA, IODINATED

T1A + LOW OSMOLAR ANGIO-UROGRAPHY

T1B + IONIC ANGIO-UROGRAPHY

WHO (Substance based)

EphMRA (Product based)

V08B	X.RAY CONTRAST MEDIA, NON-IODINATED	T1D	CHOLECYSTOGRAPHY AND CHOLANGIOGRAPHY
V08C	MAGNETIC RESONANCE IMAGING CONTRAST MEDIA	T1C	GASTROENTEROGRAPHY
V08D	ULTRASOUND CONTRAST MEDIA	T1E	MRI AGENTS
		❖	
		T1F	ULTRASOUND AGENTS
		T1X	OTHER IMAGING AGENTS

V09	DIAGNOSTIC RADIOPHARMACEUTICALS	❖	Classified in group T
		T1G	RADIODIAGNOSTIC AGENTS

V10	THERAPEUTIC RADIOPHARMACEUTICALS	V3C	RADIOPHARMACEUTICALS
	➤ Ibritumomab tiuxetan, tositumomab and iodine (131I) tositumomab are classified here.		➤ Ibritumomab tiuxetan, tositumomab and iodine (131I) tositumomab are classified in L1X.

V20	SURGICAL DRESSINGS	❖	
------------	---------------------------	---	--
